All stock lists
Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
Healthcare · Biotechnology
9.58-0.23 (-2.35%)
Insider Score
––Not scored
ZVRA Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
ZVRA Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 39.66 M | 36.22 M | 34.13 M | 26.06 M | 25.88 M | — |
| Revenue Growth (YoY) | 53.25 % | — | — | — | — | — |
| Cost of Revenue | 1.52 M | 1.90 M | 1.52 M | 1.24 M | 12.38 M | — |
| Gross Profit | 38.14 M | 34.32 M | 32.60 M | 24.82 M | 13.50 M | — |
| SG&A Expense | 16.56 M | 20.78 M | 20.35 M | 16.93 M | 20.78 M | — |
| R&D Expense | 4.49 M | 4.39 M | 2.62 M | 3.43 M | 3.43 M | — |
| Operating Expenses | 21.36 M | 25.49 M | 23.29 M | 20.68 M | 25.83 M | — |
| Operating Income | 16.78 M | 8.83 M | 9.31 M | 4.14 M | -12.33 M | — |
| Pretax Income | 12.79 M | 44.80 M | 12.67 M | -977.00 K | 76.91 M | — |
| Tax Provision | 4.04 M | 6.91 M | 501.00 K | -433.00 K | 2.20 M | — |
| Net Income | 8.75 M | 37.89 M | 12.16 M | -544.00 K | 74.71 M | — |
| EPS (Basic) | 0.14 | 0.62 | — | -0.01 | 1.24 | -0.06 |
| EPS (Diluted) | 0.14 | 0.60 | — | -0.01 | 1.21 | -0.06 |
| Shares Outstanding | 59.16 M | 58.41 M | — | 55.95 M | 54.78 M | 54.10 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.